PMC9849371_01
PET-CT findings of the patient. (A) In September 2020, there was an irregular soft tissue mass in the upper outer quadrant of the breast (4.1 x 2.0 cm), with an SUVmax of 23.0, as shown by the blue arrow. (B) In November 2021, there were a cardiac mass (6.0 x 4.4 cm), with an SUVmax of 10.5, as shown by the yellow arrow and a diffusely thickened pericardium, with an SUVmax of 2.0, as shown by the green arrow. (C) In November 2021, there was an abnormal uptake in the liver, with an SUVmax of 5.0 and a Deauville score of 5 points, as shown by the red arrow.
fimmu-13-1052336-g001.jpg
PMC9849371_01_fimmu-13-1052336-g001.jpg
f1
PET-CT revealed progressive disease, with a maximum standard uptake value (SUVmax) of 23.0 and a Deauville score of 5 points ( Figure 1A ). On the 12th day after presentation, PET-CT of the body and head was performed, which showed cardiac involvement and abnormal uptake in the liver ( Figures 1B, C ).
Serum cytokines and CAR19 DNA. (A) Serum cytokines of the patient during CAR T-cell therapy since admission. (B) CAR19 DNA in PB and BM since CAR T-cell therapy.
fimmu-13-1052336-g002.jpg
PMC9849371_01_fimmu-13-1052336-g002.jpg
f2
The level of serum cytokines was significantly increased ( Figure 2A ). The results of CAR T cells are shown in  Figure 2B .
Clinical course of the patient. TBI+CTX+Flu+IDA+ATG, total body irradiation, cyclophosphamide, fludarabine, idarubicin, and antithymocyte globulin. BM, bone marrow aspirate; US, ultrasound; MP, methylprednisolone.
fimmu-13-1052336-g003.jpg
PMC9849371_01_fimmu-13-1052336-g003.jpg
f3
The clinical course of the patient is shown in  Figure 3 .